|
[1]
|
刁夏尧, 郭超, 金榆凯, 等. 中国癌症现状分析: 基于2024年全球流行病学数据[J]. 癌症, 2025, 44(7): 350-369.
|
|
[2]
|
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. https://doi.org/10.3322/caac.21834
|
|
[3]
|
Lei, J., Ploner, A., Elfström, K.M., Wang, J., Roth, A., Fang, F., et al. (2020) HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine, 383, 1340-1348. https://doi.org/10.1056/nejmoa1917338
|
|
[4]
|
Cohen, P.A., Jhingran, A., Oaknin, A. and Denny, L. (2019) Cervical Cancer. The Lancet, 393, 169-182. https://doi.org/10.1016/s0140-6736(18)32470-x
|
|
[5]
|
Liu, H., Ye, X., Li, D., Yao, Q. and Li, Y. (2021) Incidence, Clinical Risk and Prognostic Factors for Liver Metastasis in Patients with Cervical Cancer: A Population-Based Retrospective Study. BMC Cancer, 21, Article No. 421. https://doi.org/10.1186/s12885-021-08127-6
|
|
[6]
|
谢尚丹, 胡群超, 诸海燕. 宫颈癌肝转移的治疗研究进展[J]. 临床肝胆病杂志, 2024, 40(7): 1307-1311.
|
|
[7]
|
丁鑫, 王乾印, 马亮亮, 等. 早期子宫颈癌患者术后发生肝转移的危险因素分析[J]. 中国妇幼健康研究, 2023, 34(6): 95-101.
|
|
[8]
|
Hodgson, A., Olkhov-Mitsel, E., Howitt, B.E., Nucci, M.R. and Parra-Herran, C. (2019) International Endocervical Adenocarcinoma Criteria and Classification (IECC): Correlation with Adverse Clinicopathological Features and Patient Outcome. Journal of Clinical Pathology, 72, 347-353. https://doi.org/10.1136/jclinpath-2018-205632
|
|
[9]
|
Stolnicu, S., Hoang, L., Chiu, D., Hanko-Bauer, O., Terinte, C., Pesci, A., et al. (2019) Clinical Outcomes of HPV-Associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). American Journal of Surgical Pathology, 43, 466-474. https://doi.org/10.1097/pas.0000000000001224
|
|
[10]
|
Park, K.J. (2020) Cervical Adenocarcinoma: Integration of HPV Status, Pattern of Invasion, Morphology and Molecular Markers into Classification. Histopathology, 76, 112-127. https://doi.org/10.1111/his.13995
|
|
[11]
|
Ebrahim, N.A.A., Farghaly, T.A., El-Sherif, A.A., Fahmy, A.M., Othman, M.O., Tahoun, N.S., et al. (2025) Clinicopathological Insights and Management of Liver Metastases: Current Advances and Future Perspectives. World Journal of Hepatology, 17, Article ID: 110026. https://doi.org/10.4254/wjh.v17.i10.110026
|
|
[12]
|
Kim, G.E., Lee, S.W., Suh, C.O., Park, T.K., Kim, J.W., Park, J.T., et al. (1998) Hepatic Metastases from Carcinoma of the Uterine Cervix. Gynecologic Oncology, 70, 56-60. https://doi.org/10.1006/gyno.1998.5037
|
|
[13]
|
Yin, Z., Tang, H., Li, L., Ni, J., Yuan, S., Lou, H., et al. (2019) Impact of Sites versus Number of Metastases on Survival of Patients with Organ Metastasis from Newly Diagnosed Cervical Cancer. Cancer Management and Research, 11, 7759-7766. https://doi.org/10.2147/cmar.s203037
|
|
[14]
|
Lambert, A.W., Pattabiraman, D.R. and Weinberg, R.A. (2017) Emerging Biological Principles of Metastasis. Cell, 168, 670-691. https://doi.org/10.1016/j.cell.2016.11.037
|
|
[15]
|
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., et al. (2017) Liver Sinusoidal Endothelial Cells: Physiology and Role in Liver Diseases. Journal of Hepatology, 66, 212-227. https://doi.org/10.1016/j.jhep.2016.07.009
|
|
[16]
|
Doll, K.M. (2018) Investigating Black-White Disparities in Gynecologic Oncology: Theories, Conceptual Models, and Applications. Gynecologic Oncology, 149, 78-83. https://doi.org/10.1016/j.ygyno.2017.10.002
|
|
[17]
|
Tangjitgamol, S., Levenback, C.F., Beller, U. and Kavanagh, J.J. (2004) Role of Surgical Resection for Lung, Liver, and Central Nervous System Metastases in Patients with Gynecological Cancer: A Literature Review. International Journal of Gynecological Cancer, 14, 399-422. https://doi.org/10.1136/ijgc-00009577-200405000-00001
|
|
[18]
|
Bacalbasa, N., Dima, S., Balescu, I., Brasoveanu, V. and Popescu, I. (2016) Liver Resection for Metachronous Hepatic Metastases from Cervical Cancer. HPB, 18, e692. https://doi.org/10.1016/j.hpb.2016.01.081
|
|
[19]
|
Kaseki, H., Yasui, K., Niwa, K., Mizuno, K., Inoue, T. and Ota, M. (1992) Hepatic Resection for Metastatic Squamous Cell Carcinoma from the Uterine Cervix. Gynecologic Oncology, 44, 284-287. https://doi.org/10.1016/0090-8258(92)90059-r
|
|
[20]
|
Yin, Z., Lou, H., Tang, H., Ni, J., Zhou, Q. and Chen, M. (2019) Efficacy of Radical Doses of Pelvic Radiotherapy for Primary Tumor Treatment in Patients with Newly Diagnosed Organ Metastatic Cervical Cancer. Radiation Oncology, 14, Article No. 82. https://doi.org/10.1186/s13014-019-1297-x
|
|
[21]
|
Li, H., Wu, X. and Cheng, X. (2016) Advances in Diagnosis and Treatment of Metastatic Cervical Cancer. Journal of Gynecologic Oncology, 27, e43. https://doi.org/10.3802/jgo.2016.27.e43
|
|
[22]
|
殷卓敏. 盆腔放疗在ⅣB期宫颈癌治疗中的价值研究[D]: [博士学位论文]. 苏州: 苏州大学, 2020.
|
|
[23]
|
Burd, E.M. (2003) Human Papillomavirus and Cervical Cancer. Clinical Microbiology Reviews, 16, 1-17. https://doi.org/10.1128/cmr.16.1.1-17.2003
|
|
[24]
|
Ge, Y., Zhang, Y., Zhao, K. and Zhu, H. (2022) Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer. Drug Design, Development and Therapy, 16, 3055-3070. https://doi.org/10.2147/dddt.s374672
|
|
[25]
|
Colombo, N., Dubot, C., Lorusso, D., Caceres, M.V., Hasegawa, K., Shapira-Frommer, R., et al. (2021) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. New England Journal of Medicine, 385, 1856-1867. https://doi.org/10.1056/nejmoa2112435
|
|
[26]
|
Oaknin, A., Moore, K., Meyer, T., López-Picazo González, J., Devriese, L.A., Amin, A., et al. (2024) Nivolumab with or without Ipilimumab in Patients with Recurrent or Metastatic Cervical Cancer (Checkmate 358): A Phase 1-2, Open-Label, Multicohort Trial. The Lancet Oncology, 25, 588-602. https://doi.org/10.1016/s1470-2045(24)00088-3
|
|
[27]
|
Salem, J., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., et al. (2018) Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study. The Lancet Oncology, 19, 1579-1589. https://doi.org/10.1016/s1470-2045(18)30608-9
|
|
[28]
|
王鹏焱, 林子又, 朱凯, 等. PD-1/PD-L1单抗药物抗肿瘤免疫治疗相关不良反应及超进展疾病研究进展[J]. 中国药理学与毒理学杂志, 2024, 38(1): 56-69.
|
|
[29]
|
吴红杨. 真实世界晚期宫颈癌免疫治疗疗效及影响因素分析[D]: [硕士学位论文]. 宜昌: 三峡大学, 2025.
|
|
[30]
|
Tian, B., Han, C., Wang, H., Yan, L., Ding, Z., Liu, H., et al. (2023) Effect of Liver Metastasis on the Efficacy of Immune Checkpoint Inhibitors in Cancer Patients: A Systemic Review and Meta-Analysis. Clinical & Experimental Metastasis, 40, 255-287. https://doi.org/10.1007/s10585-023-10217-7
|